Related Experiment Videos
[Clinical effectiveness of synergic therapy]
Tadeusz Płusa1, Wojciech Lubiński
1Wojskowy Instytut Medyczny, Klinika Chorób Wewnetrznych, Pneumonologii i Alergologii CSK MON, w Warszawie.
Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego
|November 5, 2004
Summary
The combination of long-acting inhaled beta2-agonists and inhaled corticosteroids is highly effective for persistent asthma. This combination therapy improves lung function, reduces exacerbations, and enhances quality of life in patients.
Area of Science:
- Respiratory Medicine
- Pharmacology
Context:
- Persistent asthma requires effective long-term management.
- Combination inhalers offer a strategic approach to treatment.
Purpose:
- To evaluate the efficacy and benefits of co-administering long-acting inhaled beta2-agonists and inhaled corticosteroids for persistent asthma.
Summary:
- Combination inhalers containing long-acting inhaled beta2-agonists and inhaled corticosteroids are superior to monotherapy.
- This combination demonstrates equivalence to separate component administration, improving lung function and quality of life.
- It significantly reduces asthma exacerbation rates in both pediatric and adult populations.
Impact:
- Combination therapy provides increased convenience and potentially improved patient compliance.
- The treatment offers favorable cost-effectiveness due to reduced exacerbations.
- This approach is a logical choice for managing moderate-to-severe asthma.